Matching the decay half-life with the biological half-life: ImmunoPET imaging with 44 Sc-labeled Cetuximab Fab fragment

doi:10.1021/bc500415x

Title: Matching the decay half-life with the biological half-life: ImmunoPET imaging with ⁴⁴ Sc-labeled Cetuximab Fab fragment

Abstract

Scandium-44 (t _1/2 = 3.9 h) is a relatively new radioisotope of potential interest for use in clinical positron emission tomography (PET). Herein, we report, for the first time, the room-temperature radiolabeling of proteins with ⁴⁴Sc for in vivo PET imaging. For this purpose, the Fab fragment of Cetuximab, a monoclonal antibody that binds with high affinity to epidermal growth factor receptor (EGFR), was generated and conjugated with N-[(R)-2-amino-3-( para-isothiocyanato-phenyl)propyl]- trans-(S,S)-cyclohexane-1,2-diamine- N,N,N',N'',N''-pentaacetic acid (CHX-A"-DTPA). The high purity of Cetuximab-Fab was confirmed by SDS-PAGE and mass spectrometry. The potential of the bioconjugate for PET imaging of EGFR expression in human glioblastoma (U87MG) tumor-bearing mice was investigated after ⁴⁴Sc labeling. PET imaging revealed rapid tumor uptake (maximum uptake of ~12% ID/g at 4 h postinjection) of ⁴⁴Sc–CHX-A"-DTPA–Cetuximab-Fab with excellent tumor-to-background ratio, which might allow for same day PET imaging in future clinical studies. Immunofluorescence staining was conducted to correlate tracer uptake in the tumor and normal tissues with EGFR expression. As a result, this successful strategy for immunoPET imaging of EGFR expression using ⁴⁴Sc–CHX-''-DTPA–Cetuximab-Fab can make clinically translatable advances to select the right population of patients for EGFR-targeted therapy and also to monitor the therapeutic efficacy of anti-EGFR treatments.

Authors:

Chakravarty, Rubel ^[1]; Goel, Shreya ^[2]; Valdovinos, Hector F. ^[2]; Hernandez, Reinier ^[2]; Hong, Hao ^[2]; Nickles, Robert J. ^[2]; Cai, Weibo ^[3]

Univ. of Wisconsin, Madison, WI (United States); Bhabha Atomic Research Centre, Mumbai (India)
Univ. of Wisconsin, Madison, WI (United States)
Univ. of Wisconsin, Madison, WI (United States); Univ. of Wisconsin Carbone Cancer Center, Madison, WI (United States)

Publication Date:: 2014-11-11

Research Org.:: Univ. of Wisconsin, Madison, WI (United States)

Sponsoring Org.:: USDOE Office of Science (SC)

OSTI Identifier:: 1345182

Grant/Contract Number:: SC0008384

Resource Type:: Accepted Manuscript

Journal Name:: Bioconjugate Chemistry

Additional Journal Information:: Journal Volume: 25; Journal Issue: 12; Journal ID: ISSN 1043-1802

Publisher:: American Chemical Society

Country of Publication:: United States

Language:: English

Subject:: 38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEAR CHEMISTRY

Citation Formats


                    Chakravarty, Rubel, Goel, Shreya, Valdovinos, Hector F., Hernandez, Reinier, Hong, Hao, Nickles, Robert J., and Cai, Weibo. Matching the decay half-life with the biological half-life: ImmunoPET imaging with 44 Sc-labeled Cetuximab Fab fragment.  United States: N. p., 2014. 
        Web.  doi:10.1021/bc500415x.

Copy to clipboard


                    Chakravarty, Rubel, Goel, Shreya, Valdovinos, Hector F., Hernandez, Reinier, Hong, Hao, Nickles, Robert J., & Cai, Weibo. Matching the decay half-life with the biological half-life: ImmunoPET imaging with 44 Sc-labeled Cetuximab Fab fragment.  United States.  doi:10.1021/bc500415x.

Copy to clipboard


                    Chakravarty, Rubel, Goel, Shreya, Valdovinos, Hector F., Hernandez, Reinier, Hong, Hao, Nickles, Robert J., and Cai, Weibo. Tue .  
        "Matching the decay half-life with the biological half-life: ImmunoPET imaging with 44 Sc-labeled Cetuximab Fab fragment".  United States.  doi:10.1021/bc500415x.  https://www.osti.gov/servlets/purl/1345182.

Copy to clipboard


                    
@article{osti_1345182,

  title        = {Matching the decay half-life with the biological half-life: ImmunoPET imaging with 44 Sc-labeled Cetuximab Fab fragment},

  author       = {Chakravarty, Rubel and Goel, Shreya and Valdovinos, Hector F. and Hernandez, Reinier and Hong, Hao and Nickles, Robert J. and Cai, Weibo},

  abstractNote = {Scandium-44 (t1/2 = 3.9 h) is a relatively new radioisotope of potential interest for use in clinical positron emission tomography (PET). Herein, we report, for the first time, the room-temperature radiolabeling of proteins with 44Sc for in vivo PET imaging. For this purpose, the Fab fragment of Cetuximab, a monoclonal antibody that binds with high affinity to epidermal growth factor receptor (EGFR), was generated and conjugated with N-[(R)-2-amino-3-(para-isothiocyanato-phenyl)propyl]-trans-(S,S)-cyclohexane-1,2-diamine-N,N,N',N'',N''-pentaacetic acid (CHX-A"-DTPA). The high purity of Cetuximab-Fab was confirmed by SDS-PAGE and mass spectrometry. The potential of the bioconjugate for PET imaging of EGFR expression in human glioblastoma (U87MG) tumor-bearing mice was investigated after 44Sc labeling. PET imaging revealed rapid tumor uptake (maximum uptake of ~12% ID/g at 4 h postinjection) of 44Sc–CHX-A"-DTPA–Cetuximab-Fab with excellent tumor-to-background ratio, which might allow for same day PET imaging in future clinical studies. Immunofluorescence staining was conducted to correlate tracer uptake in the tumor and normal tissues with EGFR expression. As a result, this successful strategy for immunoPET imaging of EGFR expression using 44Sc–CHX-''-DTPA–Cetuximab-Fab can make clinically translatable advances to select the right population of patients for EGFR-targeted therapy and also to monitor the therapeutic efficacy of anti-EGFR treatments.},

  doi          = {10.1021/bc500415x},

  journal      = {Bioconjugate Chemistry},

  number       = 12,

  volume       = 25,

  place        = {United States},

  year         = {2014},

  month        = {11}

}

Copy to clipboard

Journal Article:

Free Publicly Available Full Text

Accepted Manuscript (DOE)

Publisher's Version of Record

DOI: 10.1021/bc500415x

Other availability

Search WorldCat to find libraries that may hold this journal

Citation Metrics:

Cited by: 22 works

Citation information provided by
Web of Science

Save / Share:

Export Metadata

Save to My Library

Works referencing / citing this record:

AAZTA: An Ideal Chelating Agent for the Development of ⁴⁴ Sc PET Imaging Agents
journal, January 2017

Nagy, Gábor; Szikra, Dezső; Trencsényi, György
Angewandte Chemie International Edition, Vol. 56, Issue 8
DOI: 10.1002/anie.201611207

Similar records in OSTI.GOV collections:

Comparison of Two Site-Specifically ¹⁸F-Labeled Affibodies for PET Imaging of EGFR Positive Tumors

Journal Article Su, Xinhui ; Cheng, Kai ; Jeon, Jongho ; ... - Molecular Pharmaceutics

The epidermal growth factor receptor (EGFR) serves as an attractive target for cancer molecular imaging and therapy. Our previous positron emission tomography (PET) studies showed that the EGFR-targeting affibody molecules ⁶⁴Cu-DOTA-Z _EGFR:1907 and ¹⁸F-FBEM-Z _EGFR:1907 can discriminate between high and low EGFR-expression tumors and have the potential for patient selection for EGFR-targeted therapy. Compared with ⁶⁴Cu, ¹⁸F may improve imaging of EGFR-expression and is more suitable for clinical application, but the labeling reaction of ¹⁸F-FBEM-Z _EGFR:1907 requires a long synthesis time. The aim of the present study is to develop a new generation of ¹⁸F labeled affibody probes (Al ¹⁸F-NOTA-Zmore »« less
Cited by 24
DOI: 10.1021/mp5003043
Comparison of Two Site-Specifically ¹⁸F-Labeled Affibodies for PET Imaging of EGFR Positive Tumors

Journal Article Su, Xinhui ; Cheng, Kai ; Jeon, Jongho ; ... - Molecular Pharmaceutics

The epidermal growth factor receptor (EGFR) serves as an attractive target for cancer molecular imaging and therapy. Our previous positron emission tomography (PET) studies showed that the EGFR-targeting affibody molecules ⁶⁴Cu-DOTA-Z _EGFR:1907 and ¹⁸F-FBEM-Z _EGFR:1907 can discriminate between high and low EGFR-expression tumors and have the potential for patient selection for EGFR-targeted therapy. Compared with ⁶⁴Cu, ¹⁸F may improve imaging of EGFR-expression and is more suitable for clinical application, but the labeling reaction of ¹⁸F-FBEM-Z _EGFR:1907 requires a long synthesis time. The aim of the present study is to develop a new generation of ¹⁸F labeled affibody probes (Al ¹⁸F-NOTA-Zmore »« less
Cited by 24
DOI: 10.1021/mp5003043

Full Text Available
Development of Cu-64 labeled EGF for In Vivo PET Imaging of EGFR Expression

Technical Report Backer, Joseph M.

In this project we proposed to establish feasibility of the development of targeted tracers for radionuclide imaging of epidermal growth factor receptors (EGFR) in cancer patients. The significance and impact of the proposed radiotracers are determined by the crucial role that EGFR plays in many cancers and by the rapid entrance of EGFR-inhibiting drugs into clinic. Clinical experience, however, revealed that only 10-25% of patients that are defined as EGFR-positive by immunohistochemical analysis respond to EGFR-directed therapeutics and there is poor correlation between EGFR immunohistochemistry and treatment. Therefore, for more efficacious use of EGFR-targeting therapeutics, there is a need formore »« less
DOI: 10.2172/958568

Full Text Available
KRAS Mutation Status and Clinical Outcome of Preoperative Chemoradiation With Cetuximab in Locally Advanced Rectal Cancer: A Pooled Analysis of 2 Phase II Trials

Journal Article Kim, Sun Young ; Shim, Eun Kyung ; Yeo, Hyun Yang ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: Cetuximab-containing chemotherapy is known to be effective for KRAS wild-type metastatic colorectal cancer; however, it is not clear whether cetuximab-based preoperative chemoradiation confers an additional benefit compared with chemoradiation without cetuximab in patients with locally advanced rectal cancer. Methods and Materials: We analyzed EGFR, KRAS, BRAF, and PIK3CA mutation status with direct sequencing and epidermal growth factor receptor (EGFR) and Phosphatase and tensin homolog (PTEN) expression status with immunohistochemistry in tumor samples of 82 patients with locally advanced rectal cancer who were enrolled in the IRIX trial (preoperative chemoradiation with irinotecan and capecitabine; n=44) or the ERBIRIX trial (preoperativemore »« less
DOI: 10.1016/J.IJROBP.2012.03.048
Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes

Journal Article Wilson, Justin J. ; Ferrier, Maryline ; Radchenko, Valery ; ... - Nuclear Medicine and Biology

The use of α-emitting isotopes for radionuclide therapy is a promising treatment strategy for small micro-metastatic disease. The radioisotope ²¹³Bi is a nuclide that has found substantial use for targeted α-therapy (TAT). The relatively unexplored aqueous chemistry of Bi³⁺, however, hinders the development of bifunctional chelating agents that can successfully deliver these Bi radioisotopes to the tumor cells. Here, a novel series of nitrogen-rich macrocyclic ligands is explored for their potential use as Bi-selective chelating agents. The ligands, 1,4,7,10-tetrakis(pyridin-2-ylmethyl)-1,4,7,10-tetraazacyclododecane (L ^py), 1,4,7,10-tetrakis(3-pyridazylmethyl)-1,4,7,10-tetraazacyclododecane (L ^pyd), 1,4,7,10-tetrakis(4-pyrimidylmethyl)-1,4,7,10-tetraazacyclododecane (L ^pyr), and 1,4,7,10-tetrakis(2-pyrazinylmethyl)-1,4,7,10-tetraazacyclododecane (L ^pz), were prepared by a previously reported method and investigatedmore »« less
Cited by 5
DOI: 10.1016/j.nucmedbio.2014.12.007

Full Text Available

Similar Records

Title: Matching the decay half-life with the biological half-life: ImmunoPET imaging with 44 Sc-labeled Cetuximab Fab fragment

Abstract

Citation Formats

AAZTA: An Ideal Chelating Agent for the Development of 44 Sc PET Imaging Agents journal, January 2017

Title: Matching the decay half-life with the biological half-life: ImmunoPET imaging with ⁴⁴ Sc-labeled Cetuximab Fab fragment

AAZTA: An Ideal Chelating Agent for the Development of ⁴⁴ Sc PET Imaging Agents
journal, January 2017